Skip to main content
SpringerLink
Log in

Tumor Inflammatory Microenvironment in Lung Cancer: Heterogeneity and Implications

  • Reference work entry
  • First Online:
Handbook of Oncobiology: From Basic to Clinical Sciences

  • 100 Accesses

Abstract

Tumor diseases continue to pose a significant global health challenge, accounting for a substantial portion of human mortality. The formation and progression of tumors are intricately linked to genetic and epigenetic alterations within the cells, as well as dynamic interactions within the tumor microenvironment (TME). The TME plays a pivotal role in shaping the course of tumor diseases, particularly in the context of solid tumors like lung cancer, which exerts a profound impact on human health worldwide.

This chapter delves into the multifaceted nature of the TME, encompassing a diverse array of tumor-related cells and stromal cells that collectively contribute to tumor growth, invasion, and metastasis. Distinct physical and chemical attributes set the TME apart from the typical human environment, comprising tumor cells, fibroblasts, immune cells, vascular endothelial cells, extracellular matrix components, degrading enzymes, and a variety of growth and inflammatory factors. Interactions between tumor cells and the TME are bidirectional and dynamic, occurring through cellular or cell-free contacts and mediated by various molecular effectors. This review aims to provide an overview of the evolving understanding of the TME, highlighting its pivotal role in cancer biology and its potential as a target for therapeutic interventions. By unraveling the complexities of the TME, we may uncover novel strategies to combat tumor diseases and improve patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Al Omar S, Middleton D, Marshall E, Porter D, Xinarianos G, Raji O, Field JK, Christmas SE (2010) Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol 71:976–981

    Article  PubMed  Google Scholar 

  • Ali A, Goffin JR, Arnold A, Ellis PM (2013) Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol 20:e300–e306

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Azad N, Rojanasakul Y, Vallyathan V (2008) Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J Toxicol Environ Health B 11(1):1–15

    Article  CAS  Google Scholar 

  • Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13(2):135–141

    Article  CAS  PubMed  Google Scholar 

  • Barcellos-Hoff MH, Akhurst RJ (2010) Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res Treat 11:202–208

    Article  Google Scholar 

  • Barcellos-Hoff MH, Park C, Wright EG (2005) Radiation and the microenvironment – tumorigenesis and therapy. Nat Rev Cancer 5(867–875):194

    Google Scholar 

  • Barta JA, Powell CA, Wisnivesky JP (2019) Global epidemiology of lung cancer. Ann Glob Health 85(1):8

    Article  PubMed  PubMed Central  Google Scholar 

  • Begg AC, Stewart FA, Vens C (2011) Strategies to improve radiotherapy with targeted drugs. Nat Cancer Rev 11(239–253):195

    Google Scholar 

  • Bent R, Moll L, Grabbe S, Bros M (2018) Interleukin-1β-A friend or foe in malignancies? Int J Mol Sci 19(8):2155

    Article  PubMed  PubMed Central  Google Scholar 

  • Blumenschein GR (2012) Developmental antiangiogenic agents for the treatment of nonsmall cell lung cancer (NSCLC). Investig New Drugs 30:1802–1811

    Article  CAS  Google Scholar 

  • Blumenschein GR et al (2010) Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 16:279–290

    Article  CAS  PubMed  Google Scholar 

  • Bouquet SF, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti S et al (2011) Transforming growth factor β1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 17:6754–6765

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S et al (2011) The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 6(4):824–833. D

    Article  PubMed  Google Scholar 

  • Brenner DR, Boffetta P, Duell EJ, Bickeböller H, Rosenberger A, McCormack V et al (2012) Previous lung diseases and lung cancer risk: a pooled analysis from the international lung cancer consortium. Am J Epidemiol 176(7):573–585

    Article  PubMed  PubMed Central  Google Scholar 

  • Caetano MS, Zhang H, Cumpian AM, Gong L, Unver N, Ostrin EJ, ... Moghaddam SJ (2016) IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras–mutant lung cancer. Cancer research, 76(11):3189–3199

    Google Scholar 

  • Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734–1739

    Article  CAS  PubMed  Google Scholar 

  • Conway EM, Pikor LA, Kung SHY, Hamilton MJ, Lam S, Lam WL et al (2016) Macrophages, inflammation, and lung cancer. Am J Respir Crit Care Med 193(2):116–130

    Article  CAS  PubMed  Google Scholar 

  • Cuzick J et al (2015) Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 26:47–57

    Article  CAS  PubMed  Google Scholar 

  • Daniluk J, Liu Y, Deng D, Chu J, Huang H, Gaiser S, Cruz-Monserrate Z, Wang H, Ji B, Logsdon CD (2012) An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 122:1519–1528

    Google Scholar 

  • Daniel D, Wilson NS (2008) Tumor necrosis factor: renaissance as a cancer therapeutic?. Current cancer drug targets, 8(2):124–131

    Google Scholar 

  • Dieu-Nosjean MC et al (2008) Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26:4410–4417

    Article  CAS  PubMed  Google Scholar 

  • Drazen JM (2005) COX-2 inhibitors – a lesson in unexpected problems. N Engl J Med 352:1131–1132

    Article  CAS  PubMed  Google Scholar 

  • Du S, Barcellos-Hoff MH (2013) Biologically augmenting radiation therapy by inhibiting TGFβ actions in carcinomas. Semin Radiat Oncol 23:242–251

    Article  PubMed  PubMed Central  Google Scholar 

  • Edelman MJ, Hodgson L, Wang X, Kratzke RA, Vokes EE (2012) Cyclooxygenase-2 (COX2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer. J Clin Oncol 30:2019–2020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J et al (2007) MET amplifi cation leads to gefi tinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043

    Article  CAS  PubMed  Google Scholar 

  • Erickson AC, Barcellos-Hoff MH (2003) The not-so innocent bystander: microenvironment as a target of cancer therapy. Expert Opin Ther Targets 7(71–88):196

    Google Scholar 

  • Eskiler GG, Bezdegumeli E, Ozman Z, Ozkan AD, Bilir C, Kucukakca BN et al (2019) IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia. Bratisl Lek Listy 120(11):819–826

    Google Scholar 

  • Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, André S, Piccart M, Campone M, Brain E et al (2009) A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15:68–74

    Article  CAS  PubMed  Google Scholar 

  • Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A et al (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14:518–527

    Article  CAS  PubMed  Google Scholar 

  • Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P (2010) The polarization of immune cells in the tumour environment by TGFβ. Nat Rev Immunol 10(8):554–567

    Article  CAS  PubMed  Google Scholar 

  • Frisch J, Angenendt A, Hoth M, Prates Roma L, & Lis A (2019) STIM-Orai channels and reactive oxygen species in the tumor microenvironment. Cancers, 11(4):457

    Google Scholar 

  • Fucikova J et al (2016) Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res 76:1746–1756

    Article  CAS  PubMed  Google Scholar 

  • Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P et al (2008) Tobacco smoking and cancer: a meta-analysis. Int J Cancer 122(1):155–164

    Article  CAS  PubMed  Google Scholar 

  • Garon EB et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–673

    Article  CAS  PubMed  Google Scholar 

  • Goc J et al (2014) Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+T cells. Cancer Res 74:705–715

    Article  CAS  PubMed  Google Scholar 

  • Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA (2011) Non-small-cell lung cancer. Lancet 378:1727–1740

    Article  PubMed  Google Scholar 

  • Gomes M, Teixeira AL, Coelho A, Araújo A, Medeiros R (2014) The role of inflammation in lung cancer. Springer Basel, Porto

    Book  Google Scholar 

  • Goss GD et al (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non–small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28:49–55

    Article  CAS  PubMed  Google Scholar 

  • Greten FR, Grivennikov SI (2019) Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 51(1):27–41

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Greten FR, Eckmann L, Greten TF, Park JM, Li Z-W, Egan LJ et al (2004) IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3):285–296

    Article  CAS  PubMed  Google Scholar 

  • Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J (2005) Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol 70:419–426

    Article  CAS  PubMed  Google Scholar 

  • Hagemann T, Lawrence T, Mcneish I, Charles KA, Kulbe H, Thompson RG et al (2008) “Re-educating” tumor-associated macrophages by targeting NF-Κb. J Exp Med 205(6):1261–1268

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674

    Article  CAS  PubMed  Google Scholar 

  • Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer cell, 21(3):309–322

    Google Scholar 

  • Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K (2001) Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91:964–971

    Article  CAS  PubMed  Google Scholar 

  • Heinrich EL, Walser TC, Krysan K, Liclican EL, Grant JL, Rodriguez NL et al (2012) The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis. Cancer Microenviron 5(1):5–18

    Article  CAS  PubMed  Google Scholar 

  • Helson L, Green S, Carswell E, Old LJ (1975) Effect of tumour necrosis factor on cultured human melanoma cells. Nature 258(5537):731–732

    Article  CAS  PubMed  Google Scholar 

  • Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367–1380

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hochmuth F, Jochem M, Schlattmann P (2016) Meta-analysis of aspirin use and risk of lung cancer shows notable results. Eur J Cancer Prev 25:259–268

    Article  CAS  PubMed  Google Scholar 

  • Huang J, Xiao Z, An Y, Han S, Wu W, Wang Y, ... Shuai X (2021) Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy. Biomaterials, 269, 120636

    Google Scholar 

  • Ilie M, Long E, Hofman V, Selva E, Bonnetaud C, Boyer J, Vénissac N, Sanfi Lorenzo C, Ferrua B, Marquette CH et al (2014) Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer. Br J Cancer 110:1236–1243

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ito M, Ishii G, Nagai K, Maeda R, Nakano Y, Ochiai A (2012) Prognostic impact of cancer associated stromal cells in stage I lung adenocarcinoma patients. Chest 142:151–158

    Article  PubMed  Google Scholar 

  • Jahanban-Esfahlan A, Davaran S, Moosavi-Movahedi AA, Dastmalchi S (2017). Investigating the interaction of juglone (5-hydroxy-1, 4-naphthoquinone) with serum albumins using spectroscopic and in silico methods. Journal of the Iranian Chemical Society, 14:1527–1540

    Google Scholar 

  • Jarvis E, Kirk J, Clarke C (1998) Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. Cancer Genet Cytogenet 101:109–115

    Article  CAS  PubMed  Google Scholar 

  • Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29

    Article  PubMed  Google Scholar 

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

    Article  PubMed  Google Scholar 

  • Jin S, Mutvei AP, Chivukula IV, Andersson ER, Ramsköld D, Sandberg R et al (2013) Non-canonical notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by P53 and IKKα/IKKβ. Oncogene 32(41):4892–4902

    Article  CAS  PubMed  Google Scholar 

  • Jones LP, Li M, Halama ED, Ma Y, Lubet R, Grubbs CJ, Deng CX, Rosen EM, Furth PA (2005) Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer. Oncogene 24:3554–3562

    Article  CAS  PubMed  Google Scholar 

  • Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501:346–354

    Article  CAS  PubMed  Google Scholar 

  • Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039–2049

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim J-W, Koh Y, Kim D-W, Ahn Y-O, Kim TM, Han S-W et al (2013) Clinical implications of VEGF, TGF-Beta1, and IL-1beta in patients with advanced non-small cell lung cancer. Cancer Res Treat 45(4):325–333

    Article  PubMed  PubMed Central  Google Scholar 

  • Kirshner J, Jobling MF, Pajares MJ, Ravani SA, Glick A, Lavin M, Koslov S, Shiloh Y, Barcellos-Hoff MH (2006) Inhibition of TGFb1 signaling attenuates ATM activity in response to genotoxic stress. Cancer Res 66:10861–10868

    Article  CAS  PubMed  Google Scholar 

  • Korpanty G, Smyth E, Carney DN (2011) Update on anti-angiogenic therapy in non-small cell lung cancer: are we making progress? J Thorac Dis 3:19–29

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kundu JK, Surh YJ (2008) Inflammation: gearing the journey to cancer. Mutat Res 659(1–2):15–30

    Article  CAS  PubMed  Google Scholar 

  • Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett SM (2008) Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 66:208–217

    Article  PubMed  PubMed Central  Google Scholar 

  • Lee MK, Park JH, Gi SH, Hwang YS (2018) IL-1β induces fascin expression and increases cancer invasion. Anticancer Res 38(11):6127–6132

    Article  CAS  PubMed  Google Scholar 

  • Li B et al (2013) Elevated PLGF contributes to small-cell lung cancer brain metastasis. Oncogene 32:2952–2962

    Article  CAS  PubMed  Google Scholar 

  • Lord EM, Penney DP, Sutherland RM, Cooper RA (1979) Morphological and functional characteristics of cells infiltrating and destroying tumor multicellular spheroids in vivo. Virchows Archiv B, 31:103–116

    Google Scholar 

  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefi tinib. N Engl J Med 350:2129–2139

    Article  CAS  PubMed  Google Scholar 

  • Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549–555

    Article  CAS  PubMed  Google Scholar 

  • Mc Menamin Ú, Cardwell CR, Hughes CM, Murray LM (2015) Low-dose aspirin and survival from lung cancer: a population-based cohort study. BMC Cancer 15:911

    Article  PubMed  PubMed Central  Google Scholar 

  • McCormack VA, Hung RJ, Brenner DR, Bickeböller H, Rosenberger A, Muscat JE, Lazarus P, Tjønneland A, Friis S, Christiani DC et al (2011) Aspirin and NSAID use and lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO). Cancer Causes Control 22:1709–1720

    Article  PubMed  Google Scholar 

  • Meads MB, Gatenby RA, Dalton WS (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 9:665–674

    Article  CAS  PubMed  Google Scholar 

  • Mengxian Z, Kleber S, Roehrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U et al (2011) Blockade of TGF-beta signaling by the TGF{beta} R-I kinase Inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 71:155–167

    Google Scholar 

  • Messmer MN, Netherby CS, Banik D, Abrams SI (2015) Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol Immunother 64:1–13

    Article  CAS  PubMed  Google Scholar 

  • Müller P et al (2016) Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunol Immunother 65:1–11

    Article  PubMed  Google Scholar 

  • Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, Saijo T, Kawasaki N, Kato H (2003) cDNA microarray analysis of gene expression in pathologic stage IA nonsmall cell lung carcinomas. Cancer 97:2798–2805

    Article  CAS  PubMed  Google Scholar 

  • Nakao S, Noda K, Zandi S, Sun D, Taher M, Schering A et al (2011) VAP1-mediated M2 macrophage infiltration underlies IL-1β- but not VEGF-A induced lymph- and angiogenesis. Am J Pathol 178(4):1913–1921

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Namazi A, Forat-Yazdi M, Jafari M, Farahnak S, Nasiri R, Foroughi E et al (2018) Association of Interleukin-10 -1082 A/g (Rs1800896) polymorphism with susceptibility to gastric cancer: meta-analysis of 6,101 cases and 8,557 controls. Arq Gastroenterol 55(1):33–40

    Article  PubMed  Google Scholar 

  • Nguyen DX et al (2009) WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138:51–62

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefi tinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73

    Article  PubMed  PubMed Central  Google Scholar 

  • Paz-Ares L et al (2015) Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) Trial. J Thorac Oncol 10:1745–1753

    Article  CAS  PubMed  Google Scholar 

  • Pilotto S et al (2014) Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a ‘hard days night’. Curr Pharm Des 20:3958–3972

    Article  CAS  PubMed  Google Scholar 

  • Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumours. Nat Genet 33:49–54

    Article  CAS  PubMed  Google Scholar 

  • Ramlau R et al (2012) Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non–small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol 30:3640–3647

    Article  CAS  PubMed  Google Scholar 

  • Reck M et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15:143–155

    Article  CAS  PubMed  Google Scholar 

  • Reticker-Flynn NE, Bhatia SN (2015) Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche. Cancer Discov 5:168–181

    Article  CAS  PubMed  Google Scholar 

  • Romagnolo D, Annab L, Thompson T, Risinger J, Terry L, Barrett J, Afshari C (1998) Estrogen upregulation of BRCA1 expression with no effect on localization. Mol Carcinog 22:102–109

    Article  CAS  PubMed  Google Scholar 

  • Saito A, Horie M, Nagase T (2018) TGF-β signaling in lung health and disease. Int J Mol Sci 19(8):2460

    Article  PubMed  PubMed Central  Google Scholar 

  • Sandler A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550

    Article  CAS  PubMed  Google Scholar 

  • Scagliotti GV et al (2012) Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non–small-cell lung cancer: a phase III trial. J Clin Oncol 30:2070–2078

    Article  CAS  PubMed  Google Scholar 

  • Seike T et al (2011) Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin Exp Metastasis 28:13–25

    Article  CAS  PubMed  Google Scholar 

  • Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A et al (2008) First-line gefi tinib in patients with advanced nonsmall- cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26:2442–2449

    Article  CAS  PubMed  Google Scholar 

  • Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van Zandwijk N, Mooi WJ (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561–565

    Article  CAS  PubMed  Google Scholar 

  • Song J, Xu BB, Yao H, Lu X, Tan Y, Wang B et al (2021) Schiff-linked PEGylated doxorubicin prodrug forming pH-responsive nanoparticles with high drug loading and effective anticancer therapy. Front Oncol 11:656717

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stathopoulos P, Smith WP (2017) Analysis of survival rates following primary surgery of 178 consecutive patients with oral cancer in a large district general hospital. Journal of maxillofacial and oral surgery, 16:158–163

    Google Scholar 

  • Sterlacci W, Wolf D, Savic S, Hilbe W, Schmid T, Jamnig H et al (2012) High transforming growth factor β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer. Hum Pathol 43(3):339–349

    Article  CAS  PubMed  Google Scholar 

  • Stoll G et al (2016) Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. Onco Targets Ther 5:e1177692

    Google Scholar 

  • Tabchi S, Blais N (2017) Antiangiogenesis for advanced non-small-cell lung cancer in the era of immunotherapy and personalized medicine. Front Oncol 7:52

    Article  PubMed  PubMed Central  Google Scholar 

  • Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD (1989) p53: a frequent target for genetic abnormalities in lung cancer. Science 246:491–494

    Article  CAS  PubMed  Google Scholar 

  • Tang CH, Tan TW, Fu WM, Yang RS (2008) Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis 29:35–43

    Article  CAS  PubMed  Google Scholar 

  • Taylor J, Lymboura M, Pace P, A’hern R, Desai A, Shousha S, Coombes R, Ali S (1998) An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int J Cancer 79:334–342

    Article  CAS  PubMed  Google Scholar 

  • Teixeira AL, Araújo A, Coelho A, Ribeiro R, Gomes M, Pereira C et al (2011) Influence of TGFB1+869T>C functional polymorphism in non-small cell lung cancer (NSCLC) risk. J Cancer Res Clin Oncol 137(3):435–439

    Article  CAS  PubMed  Google Scholar 

  • Thakur S, Croce C (1999) Positive regulation of the BRCA1 promoter. J Biol Chem 274:8837–8843

    Article  CAS  PubMed  Google Scholar 

  • Vahl JM, Friedrich J, Mittler S, Trump S, Heim L, Kachler K et al (2017) Interleukin-10-regulated tumour tolerance in non-small cell lung cancer. Br J Cancer 117(11):1644–1655

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Valiente M et al (2014) Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156:1002–1016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Villano JL et al (2015) Incidence of brain metastasis at initial presentation of lung cancer. Neuro-Oncology 17:122–128

    Article  PubMed  Google Scholar 

  • Wall RJ, Shyr Y, Smalley W (2007) Nonsteroidal anti-inflammatory drugs and lung cancer risk: a population-based case control study. J Thorac Oncol 2:109–114

    Article  PubMed  Google Scholar 

  • Wang D, Dubois RN (2006) Prostaglandins and cancer. Gut 55:115–122

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang R, Lu M, Zhang J, Chen S, Luo X, Qin Y et al (2011) Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res 30(1):62

    Article  PubMed  PubMed Central  Google Scholar 

  • Wang L et al (2013) Astrocytes directly influence tumor cell invasion and metastasis in vivo. PLoS One 8:e80933

    Article  PubMed  PubMed Central  Google Scholar 

  • Wang L, Cao L, Wang H, Liu B, Zhang Q, Meng Z et al (2017) Cancerassociated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway. Oncotarget 8(44):76116–76128

    Article  PubMed  PubMed Central  Google Scholar 

  • Weichand B, Popp R, Dziumbla S, Mora J, Strack E, Elwakeel E et al (2017) S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1β. J Exp Med 214(9):2695–2713

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xu C, Brown M, Chambers J, Griffiths B, Nicolai H, Solomon E (1995) Distinct transcription start sites generate two forms of BRCA1 mRNA. Hum Mol Genet 4:2259–2264

    Article  CAS  PubMed  Google Scholar 

  • Xu C-F, Chambers J, Solomon E (1997) Complex regulation of the BRCA1 gene. J Biol Chem 272:20994–20997

    Article  CAS  PubMed  Google Scholar 

  • Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M et al (2014) Targeting Interleukin-6 in Inflammatory Autoimmune Diseases and Cancers. Pharmacol Ther 141(2):125–139

    Article  CAS  PubMed  Google Scholar 

  • Zavala VA, Kalergis AM (2015) New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 145:182–201

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P et al (2007) Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 30(4):627–632

    Article  CAS  PubMed  Google Scholar 

  • Zhang M, Herion TW, Timke C, Han N, Hauser K, Weber KJ, Peschke P, Wirkner U, Lahn M, Huber PE (2011) Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. Neoplasia 13:537–549

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zheng P, Liu Y, Chen J, Xu W, Li G, Ding J (2020) Targeted pH responsive polyion complex micelle for controlled intracellular drug delivery. Chin Chem Lett 31(5):1178–1182

    Article  CAS  Google Scholar 

  • Zheng P, Ding B, Jiang Z, Xu W, Li G, Ding J et al (2021) Ultrasoundaugmented mitochondrial calcium ion overload by calcium nanomodulator to induce immunogenic cell death. Nano Lett 21(5):2088–2093

    Article  CAS  PubMed  Google Scholar 

  • Zochbauer-Muller S, Gazdar AF, Minna JD (2002) Molecular pathogenesis of lung cancer. Annu Rev Physiol 64:681–708

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biotechnology, Thapar Institute of Engineering and Technology, Patiala, India

    Anmol Bhatia & Siddharth Sharma

  2. Department of Biotechnology, Panjab University, Chandigarh, India

    R. C. Sobti

Authors
  1. Anmol Bhatia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. C. Sobti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Siddharth Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Siddharth Sharma .

Editor information

Editors and Affiliations

  1. Dept. Biotechnology, Panjab University, Chandigarh, Chandigarh, India

    R. C. Sobti

  2. NCR Biotech Science Cluster, Translational Health Sci & Tech Inst, Faridabad, Haryana, India

    Nirmal K. Ganguly

  3. Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India

    Rakesh Kumar

Section Editor information

  1. Department of Biotechnology, Panjab University, Chandigarh, India

    Ranbir Chander Sobti

  2. Swami Rama Himalayan University, Dehradun, Kerala, India

    Rakesh Kumar

  3. NCR Biotech Science Cluster, Translational Health Science and Technology Institute, Faridabad, India

    Nirmal K. Ganguly

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Springer Nature Singapore Pte Ltd.

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Bhatia, A., Sobti, R.C., Sharma, S. (2024). Tumor Inflammatory Microenvironment in Lung Cancer: Heterogeneity and Implications. In: Sobti, R.C., Ganguly, N.K., Kumar, R. (eds) Handbook of Oncobiology: From Basic to Clinical Sciences. Springer, Singapore. https://doi.org/10.1007/978-981-99-6263-1_20

Download citation

Publish with us

Policies and ethics

Search

Navigation